Vor Bio Announces $55.6 Million Private Placement

Posted 2024-12-27, Enid News & Eagle

Intend to announce updated clinical data from Phase 1/2 VBP301 trial of VCAR33ALLOin the first half of 2025 and updated clinical data from Phase 1/2a VBP101 trial of trem-cel in combination with Mylotarg in the second half of 2025 ...... read full story

News

Search

Vor Bio Announces $55.6 Million Private Placement

Ask about this article

Related News

Vor Bio Announces $55.6 Million Private Placement Form 8 K (Vor Biopharma Inc)

PolyPid Announces Positive Recommendation by DSMB to Continue Enrollment of Phase 3 SHIELD II Trial of D PLEX100 to 800 Patients with a Concurrent Private Placement of up to $41 Million Form 6 K (PolyPid Ltd)

Assembly Biosciences Reports Interim Phase 1b Results from Clinical Trial Evaluating Next Generation Capsid Assembly Modulator Candidate ABI 4334 in Chronic Hepatitis B Form 8 K (Assembly Biosciences Inc)

Related News

Viracta Therapeutics Announces Closure of NAVAL 1 Clinical Trial and Exploration of Strategic Alternatives Form 8 K (Viracta Therapeutics Inc)

Oncology in Focus: How Emerging Therapies Are Reshaping Cancer Treatment

PainReform Provides Further Update on Phase 3 Clinical Trial of PRF 110 Form 6 K (PainReform Ltd)

180 Life Sciences Corp. Announces Pricing of $2.9 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under NASDAQ Rules

AusperBio Secures $73 Million in Series B Financing to Advance Functional Cure for Chronic Hepatitis B

Precigen Announces $79.0 Million Private Placement Offering of Convertible Preferred Stock

Annual Report for Fiscal Year Ending September 30, 2024 (Form 10-K) (Citius Pharmaceuticals Inc)

180 Life Sciences Corp. Announces Pricing of $2.9 Million Registered Direct Offering and Concurrent Private ...

EXPLORE WN.com